PharmD Info

A forum for Indian Pharmacy Professionals

New Drug Information's and other safety information, drug label changes, and Dose and Dosage Calculations, CDCSO,PvPI and FDA Safety Alerts and etc.
  • User avatar
#2017
There are few available options for treating Pulmonary hypertension in COPD and this statement may help a better understanding.

"Long-term supplemental oxygen remains the primary treatment in COPD patients with PH. The administration of new vasodilators (prostanoids, endothelin-1 receptor antagonists and phosphodiesterase-5 inhibitors) dedicated to idiopathic pulmonary arterial hypertension in the disproportionate subgroup of patients with "out-of-proportion" PH may be considered in the setting of clinical trials. The use of these drugs in COPD patients with PH < 40 mmHg may worsen gas exchange, and to date, has no proven benefit.

Further novel agents under review/trials are "5-HT receptor antagonists, Rho-kinase inhibitors, statins and stem cell therapy.

Reference:Curr Drug Targets. 2011 Apr;12(4):501-13.
Pulmonary hypertension in COPD: pathophysiology and therapeutic targets.
Zakynthinos E1, Daniil Z, Papanikolaou J, Makris D.

Greetings from Sree Dattha Institute of Pharmacy […]

Required Manager Clinical Pharmacy - Venkateswar H[…]

To, The HR Manager, MGM new Bombay hospital Navi M[…]

Vacancy for Clinical Pharmacist Job - Max Hospital[…]

PharmD Info - Highlights